Steve Pakola - 01 Nov 2026 Form 4 Insider Report for REGENXBIO Inc. (RGNX)

Reporting relationship: Chief Medical Officer
Issuer ticker: RGNX
Reported as of: 01 Nov 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Nov 2026, 16:31:49 UTC
Prior SEC filing: 04 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Patrick J. Christmas as attorney-in-fact

Filing notes and source

Key filing fact

Steve Pakola filed Form 4 for REGENXBIO Inc. (RGNX) on 03 Nov 2026.

Key facts

This page summarizes Steve Pakola's Form 4 filing for REGENXBIO Inc. (RGNX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Nov 2026, 16:31.

Change

Previous filing in this sequence was filed on 04 Aug 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001700659 Primary reporting owner

PAKOLA STEVE

Relationship: Chief Medical Officer
Address: C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE
Signature: /s/ Patrick J. Christmas as attorney-in-fact
Signature date: 03 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RGNX transaction

Common Stock

Award

Transaction value
Shares: +34,722
Change %: +17%
Price: $0.000000^*
Shares after: 240,263
Date: 01 Nov 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 1/3rd of the shares subject to the RSU award shall vest on each of November 1, 2027, November 1, 2028, and November 1, 2029, while the recipient provides continuous service to the Issuer.